MA56505A - Inhibiteurs macrocycliques de mcl-1 - Google Patents

Inhibiteurs macrocycliques de mcl-1

Info

Publication number
MA56505A
MA56505A MA056505A MA56505A MA56505A MA 56505 A MA56505 A MA 56505A MA 056505 A MA056505 A MA 056505A MA 56505 A MA56505 A MA 56505A MA 56505 A MA56505 A MA 56505A
Authority
MA
Morocco
Prior art keywords
inhibitors
mcl
macrocyclic
macrocyclic mcl
Prior art date
Application number
MA056505A
Other languages
English (en)
Inventor
Aldo Peschiulli
Frederik Jan Rita Rombouts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA56505A publication Critical patent/MA56505A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA056505A 2019-06-21 2020-06-18 Inhibiteurs macrocycliques de mcl-1 MA56505A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181605 2019-06-21

Publications (1)

Publication Number Publication Date
MA56505A true MA56505A (fr) 2022-04-27

Family

ID=67001598

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056505A MA56505A (fr) 2019-06-21 2020-06-18 Inhibiteurs macrocycliques de mcl-1

Country Status (11)

Country Link
US (1) US20220306653A1 (fr)
EP (1) EP3986902B1 (fr)
JP (1) JP7617861B2 (fr)
KR (1) KR20220024694A (fr)
CN (1) CN114641481B (fr)
AU (1) AU2020296918A1 (fr)
BR (1) BR112021025732A2 (fr)
ES (1) ES2975083T3 (fr)
MA (1) MA56505A (fr)
MX (1) MX2021015770A (fr)
WO (1) WO2020254471A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113917A1 (fr) * 2018-09-30 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Derive macrocyclique d'indole, son procede de preparation et son application en medecine
EP3781570A4 (fr) * 2018-11-22 2021-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Indoles macrocycliques servant d'inhibiteurs de mcl-1
WO2021099580A1 (fr) * 2019-11-21 2021-05-27 Janssen Pharmaceutica Nv Dérivés de sulfonyle macrocycliques utilisés en tant qu'inhibiteurs de mcl-1
PE20252386A1 (es) 2019-11-21 2025-10-10 Pharma Mar Sa Metodo de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
EP4107161A1 (fr) * 2020-02-21 2022-12-28 Janssen Pharmaceutica NV Dérivés d'indole macrocycliques en tant qu'inhibiteurs de mcl-1
CN116848126A (zh) * 2021-02-12 2023-10-03 詹森药业有限公司 大环1,3-桥联的6-氯-7-吡唑-4-基-1h-吲哚-2-羧酸酯和6-氯-7-嘧啶-5-基-1h-吲哚-2-羧酸酯衍生物作为mcl-1抑制剂用于治疗癌症

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
ES2791319T3 (es) 2016-04-22 2020-11-03 Astrazeneca Ab Inhibidores de MCL1 macrocíclicos para tratar el cáncer
TW201904976A (zh) 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Mcl-1抑制劑及其使用方法
TWI781996B (zh) 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成mcl-1抑制劑之方法
TW201920193A (zh) * 2017-08-15 2019-06-01 美商艾伯維有限公司 大環mel-1抑制劑以及使用方法
CA3113917A1 (fr) * 2018-09-30 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Derive macrocyclique d'indole, son procede de preparation et son application en medecine
EP3781570A4 (fr) 2018-11-22 2021-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Indoles macrocycliques servant d'inhibiteurs de mcl-1

Also Published As

Publication number Publication date
MX2021015770A (es) 2022-04-12
CN114641481B (zh) 2024-07-30
US20220306653A1 (en) 2022-09-29
WO2020254471A1 (fr) 2020-12-24
AU2020296918A1 (en) 2022-02-17
EP3986902B1 (fr) 2024-01-24
JP7617861B2 (ja) 2025-01-20
CA3143613A1 (fr) 2020-12-24
EP3986902A1 (fr) 2022-04-27
ES2975083T3 (es) 2024-07-03
JP2022537393A (ja) 2022-08-25
CN114641481A (zh) 2022-06-17
KR20220024694A (ko) 2022-03-03
EP3986902C0 (fr) 2024-01-24
BR112021025732A2 (pt) 2022-04-12

Similar Documents

Publication Publication Date Title
EP4007752C0 (fr) Inhibiteurs de kif18a
PT3793565T (pt) Inibidores mcl-1
EP4007753C0 (fr) Inhibiteurs de kif18a
IL283639A (en) Kif18a inhibitors
MA54550A (fr) Inhibiteurs de kif18a
PT3958977T (pt) Derivados de camptotecina
EP4007756C0 (fr) Inhibiteurs de kif18a
EP4051676A4 (fr) Inhibiteurs de bcl-2
IL292161A (en) New methylquinazolinone derivatives
EP3788042A4 (fr) Inhibiteurs de bcl-2
MA52812A (fr) Inhibiteurs de sarm1
LT3445767T (lt) Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui
IL290561A (en) Alkynyl quinazoline compounds
MA52813A (fr) Inhibiteurs de sarm1
MA56505A (fr) Inhibiteurs macrocycliques de mcl-1
EP3980011A4 (fr) Inhibiteurs de sarm1
EP3883573A4 (fr) Inhibiteurs macrocycliques de dyrk1a
PT3746446T (pt) Inibidores de prc2
EP3817736A4 (fr) Inhibiteurs de pikfyve
MA52809A (fr) Inhibiteurs de sarm1
EP4013751C0 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
DK3783000T3 (da) Makrocyklisk kinasehæmmer
EP4077334C0 (fr) Dérivés furoindazole
EP4021904C0 (fr) Dérivés d'alpha-d-galactopyranoside
DK3898637T3 (da) Rapamycin-derivater